Details
A BIG Leap for Indian Pharma Innovation! 🇮🇳
Can India develop a breakthrough therapy for one of the world's most neglected genetic disorders?
Zydus Lifesciences has just moved one step closer.
The company has received approval to initiate a Phase III clinical trial for Desidustat in the treatment of Sickle Cell Disease (SCD) in collaboration with ICMR—a landmark development that could reshape the future of rare disease management in India.